Testosterone Levels by Age Statistics (2026)

Testosterone by age, at a glance

Total testosterone peaks in the early twenties and then declines steadily, by roughly 1 to 2 percent per year after age 30. The drop is gentle in any single year and compounds across decades. Here is the trajectory.

Representative midpoints synthesized from clinical age-stratified references; the ~1 to 2% annual decline is well established. Ranges vary by lab and assay.

Reference ranges by decade

A single median hides how wide "normal" is. The chart below shows the full reported range at each decade as a vertical band, from the low end to the high end. The band drifts down and narrows with age. This is why your decade matters: a reading of 350 ng/dL sits near the floor for a 25 year old and closer to the middle for a 70 year old.

Representative ranges compiled from major clinical lab references; differ by lab and assay.

Where the research-grade range comes from

The most rigorous figures come from a 2017 study in the Journal of Clinical Endocrinology & Metabolism that harmonized testosterone assays across four large cohorts in the US and Europe. In healthy non-obese men aged 19 to 39, the normal range ran from 264 to 916 ng/dL, with a median near 531. The distribution looks like this.

Travison et al., JCEM 2017. academic.oup.com

Total and free testosterone fall at different speeds

Two numbers matter, and they decline at different rates. Total testosterone is everything in the bloodstream. Free testosterone, the unbound fraction your body can actually use, is only about 1 to 4 percent of the total. As men age, sex hormone binding globulin (SHBG) rises and binds more testosterone, so free testosterone falls faster than the total reading suggests.

This is why two men with an identical total of 450 ng/dL can feel completely different: the one with high SHBG has less usable free testosterone. It is also why a full picture needs total T, free T, and SHBG, not just the headline number.

Free-testosterone fraction and SHBG dynamics per endocrinology literature; testing timing per AUA and Endocrine Society guidance.

Why a slow decline still adds up

A 1 percent yearly drop sounds trivial. Compounded across four decades it is not. Starting from a man's age-30 level, even a conservative 1 percent annual decline leaves him roughly a third lower by age 70.

Author projection compounding a 1% annual decline; shown to illustrate the math, not a specific dataset.

How common is low testosterone by age

Prevalence climbs steeply each decade. In the Baltimore Longitudinal Study of Aging, the share of men with low testosterone rose from roughly 12 percent in their 50s to about 49 percent by their 80s. Estimates vary by the cutoff used, which is part of the story: the threshold defines the diagnosis.

A separate study, Hypogonadism in Males (HIM), put overall prevalence near 39 percent in men aged 45 and older. Yet most men who qualify never get treated: estimates suggest only 5 to 35 percent of hypogonadal men actually receive therapy.

Baltimore Longitudinal Study of Aging and the HIM study, via male hypogonadism epidemiology reviews (PMC). pmc.ncbi.nlm.nih.gov

The generational decline

The age chart is only half the picture. Reference ranges are not fixed across time, and men today have meaningfully lower testosterone than men the same age a generation ago. US national survey data (NHANES) shows average total testosterone in young men fell from 605 ng/dL in 1999 to 2000 to 451 ng/dL in 2015 to 2016, about 25 percent.

The decline held even among men with a healthy body weight, falling from 665 to 529 ng/dL (about 20 percent), which rules out obesity as the sole cause. An earlier population study reported a comparable age-independent drop of roughly 1 percent per year across the late 1980s to early 2000s. Suspected drivers include rising body fat, sedentary lifestyles, sleep loss, and environmental endocrine disruptors.

Lokeshwar et al., European Urology Focus 2021 (NHANES 1999–2016), via Urology Times; and Travison et al., JCEM 2007. urologytimes.com

What moves testosterone: the levers

Within a man's age-appropriate range, daily habits push the number up or down, and some effects are fast and large. The chart below summarizes the direction and relative strength of the main levers.

Sleep figure: Leproult & Van Cauter, JAMA 2011. pubmed.ncbi.nlm.nih.gov. Other effects directional, per published endocrinology literature.

How the treatment market has changed

Testosterone therapy has moved from a niche treatment for diagnosed hypogonadism to a mainstream, direct-to-consumer category. US prescriptions rose from 7.3 million in 2019 to more than 11 million in 2024, an increase of roughly 50 percent in five years.

CBS News, 2025. cbsnews.com

Younger men are driving the surge

The growth is not coming from elderly men with diagnosed deficiency. Between 2018 and 2022, the prevalence of testosterone therapy more than doubled among men 24 and under, and rose 86 percent among men 25 to 34. The older the group, the slower the growth.

Selinger & Thallapureddy, PLoS One 2024, via U.S. Pharmacist (state prescription drug monitoring data, 2018–2022). uspharmacist.com

Formats, price, and the rules

The category itself is shifting. Injectables still hold the largest share at roughly 55 percent, but newer formats, oral capsules, nasal sprays, and autoinjectors, are disrupting a market long built on gels, patches, injections, and pellets. Telehealth and clinic chains have made access faster and cheaper: testosterone therapy prices fell about 4.2 percent per year from 2018 to 2022.

Regulation and evidence are catching up to demand. The TRAVERSE trial, which followed 5,246 men aged 45 to 80, found that testosterone therapy did not raise the risk of major cardiac events in the studied population, and the American Urological Association issued an updated testosterone-deficiency guideline in 2024. Even so, a diagnosis is never a single number: it requires consistently low testosterone on repeat morning testing plus symptoms, which is why monitoring matters as much as the prescription.

Format share: Mordor Intelligence. Price trend: U.S. Pharmacist citing CMS data. Market value: GMInsights and others. FDA labeling update, Feb 2025; TRAVERSE, NEJM 2023; AUA 2024 guideline.

Sources

• Travison TG, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the US and Europe. JCEM, 2017. academic.oup.com
• Lokeshwar SD, et al. Decline in Serum Testosterone Levels Among Adolescent and Young Adult Men in the USA. European Urology Focus, 2021 (NHANES 1999–2016). urologytimes.com
• Travison TG, et al. A Population-Level Decline in Serum Testosterone Levels in American Men. JCEM, 2007.
• Harman SM, et al. Baltimore Longitudinal Study of Aging; male hypogonadism epidemiology reviews. pmc.ncbi.nlm.nih.gov
• Leproult R, Van Cauter E. Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men. JAMA, 2011. pubmed.ncbi.nlm.nih.gov
• CBS News. Testosterone Replacement Therapy Surges in Popularity, 2025 (prescription growth 7.3M to 11M). cbsnews.com
• Selinger & Thallapureddy. Nationwide Patterns in Testosterone Replacement Therapy. PLoS One, 2024, via U.S. Pharmacist (PDMP data 2018–2022; growth by age, price trend). uspharmacist.com
• TRAVERSE cardiovascular safety trial, New England Journal of Medicine, 2023; FDA testosterone labeling update, Feb 2025; AUA testosterone deficiency guideline, 2024.
• Market size and formulation share: Mordor Intelligence and GMInsights, 2025 to 2026.
• American Urological Association and Endocrine Society clinical guidance on testosterone testing and diagnosis.

This article is for general education and is not medical advice. Reference ranges vary by laboratory and assay. Discuss your own results with a qualified clinician.